Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 793242, 11 pages
http://dx.doi.org/10.1155/2014/793242
Research Article

Experimental Protection of Diabetic Mice against Lethal P. aeruginosa Infection by Bacteriophage

1Department of Biotechnology, Gulbarga University, Gulbarga, Karnataka 585106, India
2Luqman College of Pharmacy, Gulbarga, Karnataka 585101, India
3Department of Pathology, M. R. Medical College, Gulbarga, Karnataka 585104, India
4Department of Neuromicrobiology, NIMHANS, Bangalore, Karnataka 560 029, India

Received 18 February 2014; Revised 9 April 2014; Accepted 9 May 2014; Published 5 June 2014

Academic Editor: Ranadhir Chakraborty

Copyright © 2014 Nagaveni Shivshetty et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The emergence of antibiotic-resistant bacterial strains has become a global crisis and is vulnerable for the exploration of alternative antibacterial therapies. The present study emphasizes the use of bacteriophage for the treatment of multidrug resistant P. aeruginosa. P. aeruginosa was used to induce septicemia in streptozotocin (STZ) induced diabetic and nondiabetic mice by intraperitoneal (i.p.) injection of 3 × 108 CFU, resulting in a fatal bacteremia within 48 hrs. A single i.p. injection of 3 × 109 PFU phage GNCP showed efficient protection in both diabetic (90%) and nondiabetic (100%) bacteremic mice. It was further noted that the protection rate was reduced in diabetic mice when phage GNCP was administered after 4 h and 6 h of lethal bacterial challenge. In contrast, nondiabetic bacteremic mice were rescued even when treatment was delayed up to 20 h after lethal bacterial challenge. Evaluation of results confirmed that a single intraperitoneal injection of the phage dose (3 × 109 PFU/mL) was more effective than the multiple doses of imipenem. These results uphold the efficacy of phage therapy against pernicious P. aeruginosa infections, especially in cases of immunocompromised host.